The emergence of targeted therapies over the last decade and a half has reshaped the treatment landscape for many cancers; with huge benefits to life expectancy and patient health as a result of a number of innovations. This “targeted revolution” is ongoing in many disease areas (Chronic Myeloid Leukaemia, Chromic Lymphocytic Leukaemia, Non-Small Cell Lung Cancer), whilst it is yet to occur in others (Pancreatic Cancer, Liver Cancer).

The industry requires a tool which has the capacity to meet tomorrow’s world, which must have the capability and flexibility to perform the tasks required of it, whilst maintaining accuracy, and a straight forward user approach.

Read more…

Quote Request